Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Emerg Drugs. 2012 Sep;17(3):361-78. doi: 10.1517/14728214.2012.702755. Epub 2012 Jul 19.

Emerging drugs for bronchiectasis.

Author information

1
Queensland Children's Medical Research Institute, Royal Children's Hospital, Queensland. annechang@ausdoctors.net

Abstract

INTRODUCTION:

The global burden of disease due to bronchiectasis is high, disproportionately impacting developing countries and disadvantaged populations. Bronchiectasis, the destruction and dilation of airways, is due to a variety of causes and is characterized by a self-perpetuating cycle of airway inflammation, infection and obstruction that results in substantial morbidity and mortality. Although many therapies have been tested that address each of these three components, as well as the diseases that both cause and result from bronchiectasis, there have been few randomized, placebo-controlled trials.

AREAS COVERED:

In this review, current knowledge of the clinical features, pathophysiology and epidemiology of bronchiectasis among both adults and children is summarized. We discuss the quality and extent of evidence supporting current treatment strategies, focusing on therapies for which the strongest evidence of efficacy exists. We then identify key goals for future research on the causes and treatments of a variety of types of bronchiectasis.

EXPERT OPINION:

Significant advances in the prevention and treatment of bronchiectasis will require substantially improved understanding of the pathogenesis of this orphan disease. A concerted, global effort to coordinate studies of both the pathophysiology and potential treatments of bronchiectasis, in its many forms, could lead to substantial improvements in outcomes.

PMID:
22809423
DOI:
10.1517/14728214.2012.702755
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center